000			01840 a2200517 4500
005			20250517194150.0
264		0	_c20180223
008			201802s 0 0 eng d
022			_a1538-8689
024	7		_a10.1097/01.NURSE.0000529803.83288.e1 _2doi
040			_aNLM _beng _cNLM
100	1		_aHussar, Daniel A
245	0	0	_aNew Drugs 2018, part 1. _h[electronic resource]
260			_bNursing _cFeb 2018
300			_a36-44 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAminoisobutyric Acids
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Neutralizing _xtherapeutic use
650	0	4	_aAntipyrine _xanalogs & derivatives
650	0	4	_aBenzamides _xtherapeutic use
650	0	4	_aBenzimidazoles _xtherapeutic use
650	0	4	_aBroadly Neutralizing Antibodies
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCyclopropanes
650	0	4	_aDrug Approval
650	0	4	_aDrug Combinations
650	0	4	_aEdaravone
650	0	4	_aHeterocyclic Compounds, 4 or More Rings _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aLactams, Macrocyclic
650	0	4	_aLeucine _xanalogs & derivatives
650	0	4	_aMacrocyclic Compounds _xtherapeutic use
650	0	4	_aNaltrexone _xanalogs & derivatives
650	0	4	_aNatriuretic Peptides _xtherapeutic use
650	0	4	_aProline _xanalogs & derivatives
650	0	4	_aPyridines _xtherapeutic use
650	0	4	_aPyrrolidines
650	0	4	_aQuinoxalines _xtherapeutic use
650	0	4	_aSofosbuvir _xtherapeutic use
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aUnited States
650	0	4	_aUnited States Food and Drug Administration
773	0		_tNursing _gvol. 48 _gno. 2 _gp. 36-44
856	4	0	_uhttps://doi.org/10.1097/01.NURSE.0000529803.83288.e1 _zAvailable from publisher's website
999			_c27970847 _d27970847